ARTICLE | Finance
Developers of vaccines, obesity drugs among those with heavier losses
By Paul Bonanos, Director of Biopharma Intelligence
November 16, 2024 12:11 AM UTC
Biotech investors’ skittish reaction to President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to lead HHS, combined with a signal that the Fed may slow-walk upcoming rate cuts, sent sector indexes down in a slide that began Thursday afternoon and continued across Friday’s session.
Biopharmas were among the worst performers as markets broadly trended down on Friday. Indexes specific to biotech underperformed the NASDAQ Composite, which was off 2.2%; the SPDR S&P Biotech ETF (XBI) sank 5.3% and the NASDAQ Biotechnology Index (NBI) fell 4.4%…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654221/biotech-indexes-fall-after-rfk-jr-nomination-fed-s-signals-on-rate-cut